These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 24029000)

  • 1. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 'either test positive' strategy for latent tuberculous infection before anti-tumour necrosis factor treatment.
    Jung YJ; Lee JY; Jo KW; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2014 Apr; 18(4):428-34. PubMed ID: 24670697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.
    Chang B; Park HY; Jeon K; Ahn JK; Cha HS; Koh EM; Kang ES; Koh WJ
    Clin Rheumatol; 2011 Dec; 30(12):1535-41. PubMed ID: 21556777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.
    Li CR; Mao QX; Chen M; Jia WX; Yao X; Feng SY; Jia H; Gong JQ; Yang XY
    Drug Des Devel Ther; 2015; 9():5591-4. PubMed ID: 26508833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.
    Lee H; Park HY; Jeon K; Jeong BH; Hwang JW; Lee J; Cha HS; Koh EM; Kang ES; Koh WJ
    PLoS One; 2015; 10(3):e0119260. PubMed ID: 25746854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA.
    Jeong DH; Kang J; Jung YJ; Yoo B; Lee CK; Kim YG; Hong S; Shim TS; Jo KW
    PLoS One; 2018; 13(7):e0198756. PubMed ID: 29975703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
    Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
    Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection.
    Lee EH; Kang YA; Leem AY; Park MS; Kim YS; Kim SK; Chang J; Kim SY
    Sci Rep; 2017 Jul; 7(1):6473. PubMed ID: 28743918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
    Bonfiglioli KR; Ribeiro AC; Moraes JC; Saad CG; Souza FH; Calich AL; Bonfa E; Laurindo IM
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):905-11. PubMed ID: 25199003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.